AHRQ Comparative Research Should Focus On Diseases, Not Drug Classes, PhRMA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Outcomes research priority should be treatment options for diseases with a high prevalence among Medicare and Medicaid beneficiaries, PhRMA says. Payor comments specify therapeutic classes where comparative data is needed most.
You may also be interested in...
Rx Comparative Effectiveness Research Funding May Be Delayed Until After Elections
Current version of the HHS funding bill does not include appropriations for a comparative research agenda authorized under the Medicare law. AHRQ will nevertheless submit initial research priorities to Congress in the next couple of weeks.
Rx Comparative Effectiveness Research Funding May Be Delayed Until After Elections
Current version of the HHS funding bill does not include appropriations for a comparative research agenda authorized under the Medicare law. AHRQ will nevertheless submit initial research priorities to Congress in the next couple of weeks.
AHRQ Research Priorities Should Include Quality Of Cardiovascular Care, Guidant Says
The agency should research a potential disparity in cardiovascular care between men and women, and the clinical and economic benefits of early screening for carotid artery disease, Guidant says. The device industry has also raised new technology underutilization and e-health as potential topics.